Regeneus Ltd (ASX: RGS), a clinical-stage regenerative medicine company, today announced that the State Intellectual Property Office of the People’s Republic of China had granted a patent covering the use of the company’s stem cell secretions technology for the topical treatment of acne.
The patent (No ZL201280022199.7), entitled “Use of a composition comprising adipose tissue-derived secretions in the manufacture of a medicament for topical treatment or prevention of acne in a subject,” provides commercial rights in China through to 15 March 2032. This is the first Regeneus patent to be granted in China.
The company’s secretions technology utilises the molecules (including exosomes, cytokines and growth factors) that are secreted by mesenchymal stem cells (MSCs). Regeneus has developed technology and protocols for the production of secretions of MSCs.
Skin conditions and wound healing are one of the most promising and near-term areas for cell-based regenerative medicine products. With few treatment innovations or improvements in the treatment of acne over the last 10 years, the demand for new improved acne treatments is high. The global market for acne-based prescription treatments is over $3billion per annum.
The granted patent will be specific for the topical treatment of acne, however, Regeneus has additional patent applications that cover the use of the secretions technology for other skin conditions.